The approval of Biogen’s Alzheimer’s treatment could herald a new generation of therapies, but before that can happen, more investment and better diagnostics may be needed, explains Ben Har
Spark Therapeutics has secured the exclusive rights to CombiGene’s CG01 therapy, which aims to treat drug resistant focal epilepsy, in a deal worth $8.5m in advance with further payments due on rea
